Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $15
Needham analyst Chad Messer maintains PhaseBio Pharmaceuticals (NASDAQ: PHAS) with a Buy and lowers the price target from $16 to $15.Needham analyst Chad Messer maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target f
